ADA and breast cancer: Zhao et al. [53] study showed that MT2A promotes oxaliplatin resistance in colorectal cancer cells, SHC1 is a key driver of breast cancer initiation [54], CEBPB can regulate stemness and chemo-resistance of gastric cancer [55], and ADA tends to have a positive association with breast cancer [56].